March 8th 2024
In an interview with Targeted Oncology, Rohan Garje, MD, discussed how mutations such as TP53, RB1, and PTEN impact overall survival in patients with metastatic prostate cancer.
February 3rd 2024
What’s in Your Basket? Tumor Agnostic Trials and the Reshaping of Precision Medicine in Oncology: A Focus on TSC1/2 Mutations
View More
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Future Directions in Urothelial Cancer Treatment: Clinical Trials and Novel Agents
September 21st 2023Arlene Siefker-Radtke, MD, highlights the ongoing quest for improved treatment options in metastatic urothelial cancer, emphasizing the role of clinical trials and novel agents in addressing unmet needs.
Watch
Second-Line Strategies in Metastatic Urothelial Cancer: Balancing Options and Risks
September 21st 2023Arlene Siefker-Radtke, MD, delves into the complexities of managing progressive disease in metastatic urothelial cancer, outlining considerations for immune checkpoint inhibitors, antibody drug conjugates, and other targeted therapies.
Watch
Frontline Options for Metastatic Urothelial Cancer: Tailoring Treatment Choices
September 21st 2023Diverse approaches to frontline treatment for metastatic urothelial cancer, including eligibility for cisplatin-based chemotherapy, alternative regimens, and the impact of drug shortages on treatment decisions.
Watch
Early Mutation Profiling in Urothelial Cancer: A Path to Targeted Therapy
September 21st 2023Arlene Siefker-Radtke, MD, emphasizes the importance of early mutation profiling in metastatic urothelial cancer and highlights the potential for targeted agents and clinical trials to improve treatment outcomes.
Watch
Biomarker Testing in Urothelial Cancer: Implications for Treatment Decisions
September 21st 2023The evolving role of biomarker testing, including PD-L1 expression and mutations like FGFR3, in guiding treatment decisions for urothelial cancer patients, shedding light on their clinical significance and potential impact on therapeutic choices.
Watch
Challenges in Treating Metastatic Urothelial Cancer: A Geriatric Perspective
September 21st 2023Expert insight into the complexities of managing metastatic urothelial cancer in geriatric patients with comorbidities, highlighting the importance of aggressive therapy in improving survival outcomes.
Watch
TALAPRO-2: First-Line Therapy for Metastatic Castration-Resistant Prostate Cancer
July 13th 2023Toni Choueiri, MD, joins the Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, to discuss recent updates from TALAPRO-2, which studied talazoparib plus enzalutamide in first-line metastatic castration-resistant prostate cancer.
Watch
FDA Approves Lu 177 Vipivotide Tetraxetan for Metastatic Castration-Resistant Prostate Cancer
March 23rd 2022The FDA has granted approval to the agent formerly known as 177Lu-PSMA-617 for the treatment of patients with metastatic castration-resistant prostate cancer in the post androgen receptor pathway inhibition, post-taxane-based chemotherapy setting.
Read More